Detalles de la búsqueda
1.
Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
J Oncol Pharm Pract
; 29(1): 191-207, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35793068
2.
International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.
J Oncol Pharm Pract
; 29(5): 1065-1074, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35382638
3.
Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study.
J Oncol Pharm Pract
; 28(7): 1560-1567, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34559022
4.
Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.
Support Care Cancer
; 29(3): 1699-1709, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32776163
5.
International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care.
J Oncol Pharm Pract
; 27(4): 785-801, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34024179
6.
Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.
J Cancer Res Clin Oncol
; 149(11): 8655-8662, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37115271
Resultados
1 -
6
de 6
1
Próxima >
>>